EGF/ErbB receptor family in ovarian cancer.

Nita Jane Maihle, A. T. Baron, B. A. Barrette, C. H. Boardman, T. A. Christensen, E. M. Cora, J. M. Faupel-Badger, T. Greenwood, S. C. Juneja, J. M. Lafky, H. Lee, J. L. Reiter, K. C. Podratz

Research output: Contribution to journalReview article

94 Citations (Scopus)

Abstract

In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)247-258
Number of pages12
JournalCancer treatment and research
Volume107
StatePublished - Jan 1 2002

Fingerprint

Epidermal Growth Factor Receptor
Ovarian Neoplasms
Protein Isoforms
Ovarian Follicle
Growth
Growth and Development
Epidermal Growth Factor
Protein-Tyrosine Kinases
Epithelium
Biomarkers
Mutation
Therapeutics
Serum
Genes
Neoplasms
ErbB Receptors
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Maihle, N. J., Baron, A. T., Barrette, B. A., Boardman, C. H., Christensen, T. A., Cora, E. M., ... Podratz, K. C. (2002). EGF/ErbB receptor family in ovarian cancer. Cancer treatment and research, 107, 247-258.

EGF/ErbB receptor family in ovarian cancer. / Maihle, Nita Jane; Baron, A. T.; Barrette, B. A.; Boardman, C. H.; Christensen, T. A.; Cora, E. M.; Faupel-Badger, J. M.; Greenwood, T.; Juneja, S. C.; Lafky, J. M.; Lee, H.; Reiter, J. L.; Podratz, K. C.

In: Cancer treatment and research, Vol. 107, 01.01.2002, p. 247-258.

Research output: Contribution to journalReview article

Maihle, NJ, Baron, AT, Barrette, BA, Boardman, CH, Christensen, TA, Cora, EM, Faupel-Badger, JM, Greenwood, T, Juneja, SC, Lafky, JM, Lee, H, Reiter, JL & Podratz, KC 2002, 'EGF/ErbB receptor family in ovarian cancer.', Cancer treatment and research, vol. 107, pp. 247-258.
Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM et al. EGF/ErbB receptor family in ovarian cancer. Cancer treatment and research. 2002 Jan 1;107:247-258.
Maihle, Nita Jane ; Baron, A. T. ; Barrette, B. A. ; Boardman, C. H. ; Christensen, T. A. ; Cora, E. M. ; Faupel-Badger, J. M. ; Greenwood, T. ; Juneja, S. C. ; Lafky, J. M. ; Lee, H. ; Reiter, J. L. ; Podratz, K. C. / EGF/ErbB receptor family in ovarian cancer. In: Cancer treatment and research. 2002 ; Vol. 107. pp. 247-258.
@article{5a0458c58b2e494b8022d1f90069baaf,
title = "EGF/ErbB receptor family in ovarian cancer.",
abstract = "In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.",
author = "Maihle, {Nita Jane} and Baron, {A. T.} and Barrette, {B. A.} and Boardman, {C. H.} and Christensen, {T. A.} and Cora, {E. M.} and Faupel-Badger, {J. M.} and T. Greenwood and Juneja, {S. C.} and Lafky, {J. M.} and H. Lee and Reiter, {J. L.} and Podratz, {K. C.}",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "107",
pages = "247--258",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - EGF/ErbB receptor family in ovarian cancer.

AU - Maihle, Nita Jane

AU - Baron, A. T.

AU - Barrette, B. A.

AU - Boardman, C. H.

AU - Christensen, T. A.

AU - Cora, E. M.

AU - Faupel-Badger, J. M.

AU - Greenwood, T.

AU - Juneja, S. C.

AU - Lafky, J. M.

AU - Lee, H.

AU - Reiter, J. L.

AU - Podratz, K. C.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.

AB - In summary, the EGF/ErbB family of receptor tyrosine kinases has been shown to play a key role in normal ovarian follicle development, and cell growth regulation of the ovarian surface epithelium. Disregulation of these normal growth regulatory pathways, including overexpression and/or mutation of EGFR/ErbB receptor family members, as well as elements of their downstream signalling pathways, have been shown to contribute to the etiology and progression of epithelial ovarian cancer. It is, therefore, not surprising that these gene products, and their related soluble receptor isoforms may have clinical utility as tumor and/or serum biomarkers of disease activity. Moreover, since several of these soluble receptor isoforms have potent growth inhibitory activity, and are naturally occurring in the circulation, they are ideal candidates for the development of novel therapeutics for the treatment of ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0036370587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036370587&partnerID=8YFLogxK

M3 - Review article

VL - 107

SP - 247

EP - 258

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -